1-1-2020

Possible role of tryptophan and melatonin in COVID-19

Musthafa Mohamed Essa
*Sultan Qaboos University*

Hamdan Hamdan
*Alfaisal University*

Saravana Babu Chidambaram
*JSS College of Pharmacy, Mysore*

Buthainah Al-Balushi
*Sultan Qaboos University*

Gilles J. Guillemin
*Macquarie University*

*See next page for additional authors*

Follow this and additional works at: [https://scholarlycommons.pacific.edu/dugoni-facarticles](https://scholarlycommons.pacific.edu/dugoni-facarticles)

Part of the Dentistry Commons

**Recommended Citation**
[https://scholarlycommons.pacific.edu/dugoni-facarticles/510](https://scholarlycommons.pacific.edu/dugoni-facarticles/510)

This Editorial is brought to you for free and open access by the Arthur A. Dugoni School of Dentistry at Scholarly Commons. It has been accepted for inclusion in Dugoni School of Dentistry Faculty Articles by an authorized administrator of Scholarly Commons. For more information, please contact mgibney@pacific.edu.
The COVID-19 outbreak has caused a high mortality, with millions of people affected worldwide. COVID-19 infection has been reported to cause respiratory, enteric, hepatic, and neurological and neuropsychiatric complications with varied clinical severity. The prophylactic and treatment measures used for this disease varies by countries, and the World Health Organization (WHO) has also suggested other strategies to avoid the spread and management of COVID-19. The etiology of COVID-19 is still mostly unknown. Therefore, identifying the mechanisms that promote viral transmission and disease infection is critical in order to overcome this pandemic situation. Furthermore until, there are no vaccines or therapeutic drugs available for COVID-19. Multiple drugs that may provide non-specific action, namely antiviral drugs (eg, remdesivir) and antimalarial drugs (eg, chloroquine and hydroxychloroquine), are being clinically screened for treatment of COVID-19 patients. Systemic complications related to COVID-19 infection are being treated with therapeutic drugs such as corticosteroid (dexamethasone) or biological agents (antibodies) against the cytokine storm (interleukins: IL-1 and IL-6, and TNF-α). Kinase inhibitors are also being tried. Until the development of vaccines and better therapeutics, there is an urgent need for strategies to control respiratory infection and to boost immune functions for patients suffering from COVID-19.

L-tryptophan (Trp), an essential amino acid, is the precursor of the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT), which promotes a sense of well-being and “happiness”, and plays a role in preventing mood disorders. Dietary fatty acids affecting the pro-inflammatory cytokines have been suggested to affect the metabolic fate of Trp. Tryptophan and its metabolites including melatonin have the capacity to improve the immune system and reduce inflammation in various conditions. Here, we discuss the potential of using tryptophan and its metabolites including melatonin to boost the immune system in fighting COVID-19 infection (see Figure 1).

A recent study by Gardinassi et al, revealed a high involvement of inflammatory networks and increased expression of genes involved in tryptophan metabolism in COVID19 patients. There is a definite involvement of interleukin-6 (IL-6) in the immune response in COVID-19 and IL-6 is thought to affect tryptophan catabolism in other pathophysiological conditions. Similarly, another study suggested a link between immunosuppressive therapy with tocilizumab and tryptophan metabolism in COVID-19 patients. This possibility indicates that tryptophan-rich sources could be beneficial for COVID-19 subjects. Despite enormous efforts to develop a COVID-19
vaccine, an effective and safe will, vaccine will likely not be available before 2021, which further demonstrates the need to develop quickly alternative solutions that are effective and known to be safe. Increasing evidence from several studies show that tryptophan and its metabolites including melatonin can reduce inflammatory reactions and enhance the immune system. There may also be a possibility that serotonin levels are altered in COVID-19 patients because of mental stress, which suggest a role for Trp in treatment. Trp is the precursor for melatonin (sleep hormone), which was reported to exert beneficial effects on the immune system through various physiological means (see Figure 2—adapted from Khan et al.).

In conclusion, even though Trp and its metabolites are known to be beneficial in improving the function of the immune system, the impact of Trp and its metabolites against severity of COVID-19 is still circumstantial and still needs to be demonstrated experimentally and clinically and to understand their role in personalized nutrition thus precision health to combat COVID-19.

ORCID iD
Gilles J Guillemin  https://orcid.org/0000-0001-8105-4470

REFERENCES